DE2827027C3 - Gefriergetrocknetes natives Γ-globulin-Präparat zur intravenösen Verabreichung - Google Patents
Gefriergetrocknetes natives Γ-globulin-Präparat zur intravenösen VerabreichungInfo
- Publication number
- DE2827027C3 DE2827027C3 DE2827027A DE2827027A DE2827027C3 DE 2827027 C3 DE2827027 C3 DE 2827027C3 DE 2827027 A DE2827027 A DE 2827027A DE 2827027 A DE2827027 A DE 2827027A DE 2827027 C3 DE2827027 C3 DE 2827027C3
- Authority
- DE
- Germany
- Prior art keywords
- gamma globulin
- weight
- preparation
- freeze
- intravenous administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010074605 gamma-Globulins Proteins 0.000 title claims description 51
- 238000002360 preparation method Methods 0.000 title claims description 34
- 238000001990 intravenous administration Methods 0.000 title claims description 8
- 230000003171 anti-complementary effect Effects 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 23
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 238000005194 fractionation Methods 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 5
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 5
- 239000000243 solution Substances 0.000 description 18
- 230000000295 complement effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
- 241000712079 Measles morbillivirus Species 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108010058237 plasma protein fraction Proteins 0.000 description 1
- 229940081857 plasma protein fraction Drugs 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP52087128A JPS5822085B2 (ja) | 1977-07-19 | 1977-07-19 | 静注用ガンマ・グロブリン製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2827027A1 DE2827027A1 (de) | 1979-01-25 |
| DE2827027B2 DE2827027B2 (de) | 1979-12-20 |
| DE2827027C3 true DE2827027C3 (de) | 1987-04-16 |
Family
ID=13906314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2827027A Expired DE2827027C3 (de) | 1977-07-19 | 1978-06-20 | Gefriergetrocknetes natives Γ-globulin-Präparat zur intravenösen Verabreichung |
Country Status (17)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4296027A (en) * | 1977-08-31 | 1981-10-20 | The Regents Of The University Of Minnesota | Pure intravenous human and animal gamma globulins |
| JPS55164630A (en) * | 1979-06-11 | 1980-12-22 | Green Cross Corp:The | Freeze-dried preparation of anti-hbs globulin |
| US4374763A (en) * | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
| US4396608A (en) * | 1981-08-24 | 1983-08-02 | Cutter Laboratories | Intravenously injectable immune serum globulin |
| US4499073A (en) * | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
| JPS5855432A (ja) * | 1981-09-29 | 1983-04-01 | Fujirebio Inc | 静脈注射用免疫グロブリンの製法 |
| DE3271181D1 (en) * | 1982-02-08 | 1986-06-19 | Schweiz Serum & Impfinst | Intravenously administrable human immunoglobuline and process for its preparation |
| JPS58180433A (ja) * | 1982-04-16 | 1983-10-21 | Fujirebio Inc | 免疫グロブリンから抗補体作用物質の除去法 |
| US4482483A (en) * | 1983-04-06 | 1984-11-13 | Armour Pharmceutical Company | Composition of intravenous immune globulin |
| US4617379A (en) * | 1983-06-14 | 1986-10-14 | Miles Laboratories, Inc. | High titer cytomegalovirus immune serum globulin |
| US4719290A (en) * | 1983-09-02 | 1988-01-12 | Armour Pharmaceutical Corporation | Composition of intravenous immune globulin |
| GB8406560D0 (en) * | 1984-03-13 | 1984-04-18 | Central Lab Of The Blood Donor | Organic compounds |
| US4835257A (en) * | 1984-07-07 | 1989-05-30 | Armour Pharma Gmbh | Process for preparing gamma globulin suitable for intravenous administration using peg and a citrate buffer |
| US4784845A (en) * | 1985-09-16 | 1988-11-15 | American Cyanamid Company | Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs |
| AU6948787A (en) * | 1986-03-10 | 1987-09-28 | Rubinstein, A.I. | A method for treating gammaglobulin |
| CA2049342A1 (en) * | 1989-03-27 | 1990-09-28 | Sally Bolmer | Formulations for stabilizing of igm antibodies |
| US5945098A (en) * | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| US6165467A (en) * | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
| AR048098A1 (es) * | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| JP5322405B2 (ja) * | 2007-06-07 | 2013-10-23 | 小林製薬株式会社 | タンパク質含有組成物 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE959127C (de) * | 1955-03-29 | 1957-02-28 | Schering Ag | Verfahren zur Gewinnung salzfreier, leicht loeslicher Trockenpraeparate von Proteinen, insbesondere Globulinen |
| US3607858A (en) * | 1970-03-31 | 1971-09-21 | American Cyanamid Co | Process for preparing lyophilized human blood proteins such as gamma globulin in the presence of a nonionic surfactant |
| DE2500076A1 (de) * | 1975-01-02 | 1976-07-08 | Waldemar Schneider | Verfahren zur erhoehung der intravenoesvertraeglichkeit von aus blut oder blutprodukten ausgefaellten gammaglobulinen |
| DE2606118A1 (de) * | 1975-02-18 | 1976-08-26 | Coval M L | Gamma-globuline fuer intravenoese injektion und verfahren zur herstellung von solchem gamma-globulin |
| JPS5320415A (en) * | 1976-08-06 | 1978-02-24 | Coval M L | Production of gammaa globlin capaple of administering into vein and gammaagloblin produced by said method |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK79841C (da) * | 1952-08-04 | 1955-09-12 | Behringwerke Ag | Fremgangsmåde til fremstilling af stabile γ-globulinpræparater. |
| DE1148037B (de) * | 1961-10-11 | 1963-05-02 | Behringwerke Ag | Verfahren zur Herstellung eines desaggregierten, das Komplementsystem nicht beeinflussenden Gammaglobulins |
| US3966906A (en) * | 1961-10-11 | 1976-06-29 | Behringwerke Aktiengesellschaft | Disaggregated gamma globulin and process for preparing it |
| US3466368A (en) * | 1967-06-02 | 1969-09-09 | Us Health Education & Welfare | Cleavage of human gamma globulin by means of cyanogen bromide |
| IL34079A (en) * | 1969-04-01 | 1973-02-28 | Upjohn Co | Purification of ypsilon-globulins |
| US3903262A (en) * | 1972-03-13 | 1975-09-02 | Cutter Lab | Pharmaceutical compositions comprising intravenously injectable modified serum globulin, its production and use |
| US3850903A (en) * | 1973-06-21 | 1974-11-26 | S Mankarious | Plasma volume expander prepared from cohn iv precipitate using block copolymers of ethylene oxide and polyoxypropylene |
| GB1499035A (en) * | 1975-04-10 | 1978-01-25 | Ts Nii Gematologii I Perelivan | Antistaphylococcus human immune globulin and method of preparing same |
| US4021540A (en) * | 1975-07-28 | 1977-05-03 | Ortho Diagnostics Inc. | Preparation of a hepatitis B immune globulin and use thereof as a prophylactic material |
| FR2336141A1 (fr) * | 1975-12-23 | 1977-07-22 | Trepo Christian | Nouveau medicament permettant de traiter les infections aigues ou chroniques dues au virus de l'hepatite b |
-
1977
- 1977-07-19 JP JP52087128A patent/JPS5822085B2/ja not_active Expired
-
1978
- 1978-06-06 CA CA304,887A patent/CA1093965A/en not_active Expired
- 1978-06-07 US US05/913,493 patent/US4168303A/en not_active Expired - Lifetime
- 1978-06-08 ZA ZA00783303A patent/ZA783303B/xx unknown
- 1978-06-12 GB GB787826702A patent/GB2001325B/en not_active Expired
- 1978-06-15 FR FR7817929A patent/FR2397838A1/fr active Granted
- 1978-06-15 NL NL7806486A patent/NL7806486A/xx active Search and Examination
- 1978-06-16 ES ES470855A patent/ES470855A1/es not_active Expired
- 1978-06-16 CH CH657878A patent/CH639854A5/de not_active IP Right Cessation
- 1978-06-16 AT AT441378A patent/AT359640B/de not_active IP Right Cessation
- 1978-06-19 DK DK274178A patent/DK274178A/da not_active Application Discontinuation
- 1978-06-19 BE BE188660A patent/BE868233A/xx not_active IP Right Cessation
- 1978-06-20 LU LU79846A patent/LU79846A1/xx unknown
- 1978-06-20 PT PT68199A patent/PT68199A/pt unknown
- 1978-06-20 SE SE7807040A patent/SE443717B/sv not_active IP Right Cessation
- 1978-06-20 DE DE2827027A patent/DE2827027C3/de not_active Expired
-
1984
- 1984-02-01 HK HK95/84A patent/HK9584A/xx unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE959127C (de) * | 1955-03-29 | 1957-02-28 | Schering Ag | Verfahren zur Gewinnung salzfreier, leicht loeslicher Trockenpraeparate von Proteinen, insbesondere Globulinen |
| US3607858A (en) * | 1970-03-31 | 1971-09-21 | American Cyanamid Co | Process for preparing lyophilized human blood proteins such as gamma globulin in the presence of a nonionic surfactant |
| DE2500076A1 (de) * | 1975-01-02 | 1976-07-08 | Waldemar Schneider | Verfahren zur erhoehung der intravenoesvertraeglichkeit von aus blut oder blutprodukten ausgefaellten gammaglobulinen |
| DE2606118A1 (de) * | 1975-02-18 | 1976-08-26 | Coval M L | Gamma-globuline fuer intravenoese injektion und verfahren zur herstellung von solchem gamma-globulin |
| JPS5320415A (en) * | 1976-08-06 | 1978-02-24 | Coval M L | Production of gammaa globlin capaple of administering into vein and gammaagloblin produced by said method |
Non-Patent Citations (7)
| Title |
|---|
| DE-Pat.Anm. Sch 17 627 IVa/30h v. 23.08.56 |
| Kalden - König: Blutkomponenten und Plasmaersatzmittel, 1982, S. 125-131 * |
| Prospekt, Intraglobin R, der Biotest- Seruminstitut, 2. Aufl., 1974, S. 2, 3 u. 5 * |
| Z: Diagnostik, 9, 1976, 31-37 * |
| Z: MMW, 1967, 34, 1749-52 * |
| Z: Schweiz.med.Wschr., 106, 1976, 537 * |
| Z: Voxsang, 28, 1975, 422-437 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BE868233A (fr) | 1978-10-16 |
| SE443717B (sv) | 1986-03-10 |
| LU79846A1 (fr) | 1978-12-07 |
| GB2001325B (en) | 1982-03-17 |
| AT359640B (de) | 1980-11-25 |
| SE7807040L (sv) | 1979-01-20 |
| HK9584A (en) | 1984-02-10 |
| PT68199A (en) | 1978-07-01 |
| DK274178A (da) | 1979-01-20 |
| DE2827027B2 (de) | 1979-12-20 |
| JPS5822085B2 (ja) | 1983-05-06 |
| ZA783303B (en) | 1979-07-25 |
| ATA441378A (de) | 1980-04-15 |
| NL7806486A (nl) | 1979-01-23 |
| CH639854A5 (de) | 1983-12-15 |
| ES470855A1 (es) | 1979-02-01 |
| JPS5423115A (en) | 1979-02-21 |
| FR2397838A1 (fr) | 1979-02-16 |
| US4168303A (en) | 1979-09-18 |
| DE2827027A1 (de) | 1979-01-25 |
| FR2397838B1 (US20070167544A1-20070719-C00007.png) | 1981-11-27 |
| CA1093965A (en) | 1981-01-20 |
| GB2001325A (en) | 1979-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2827027C3 (de) | Gefriergetrocknetes natives Γ-globulin-Präparat zur intravenösen Verabreichung | |
| DE2751717C2 (US20070167544A1-20070719-C00007.png) | ||
| DE4344824C1 (de) | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung | |
| DE2936047C2 (US20070167544A1-20070719-C00007.png) | ||
| DE68907124T3 (de) | Verfahren zum Stabilisieren von menschlichen Albuminlösungen und so erhaltene Lösung. | |
| EP0012156B1 (de) | Immunserumglobulin (ISG)-Präparate und Verfahren zu ihrer Herstellung | |
| DE69821741T2 (de) | Immunoglobulin enthaltende zusammensetzung | |
| EP0122909B1 (de) | Immunglobulin-G-hältige Fraktion | |
| DE10355251A1 (de) | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor | |
| DE3889938T2 (de) | Injizierbare Lösungen von Gamma-Globulin. | |
| DE2324717B2 (de) | Verfahren zur Herstellung eines stabilen AHF-Konzentrates (Faktor VUI) | |
| DE69827357T2 (de) | Menschliches Wachstumshormon enthaltende pharmazeutische Zusammensetzung | |
| EP0085747B2 (de) | Intravenös verabreichbares humanes Immunglobulin und Verfahren zu dessen Herstellung | |
| DE3781962T2 (de) | Verfahren zur hitzebehandlung von chemisch unmodifiziertem gamma-globulin. | |
| CH684164A5 (de) | Intravenös anwendbare Immunglobulinlösung. | |
| EP0120835B1 (de) | Verfahren zur Inaktivierung von Unverträglichkeitsreaktionen verursachenden Substanzen | |
| DE2639012C3 (de) | Inununtherapeutikum zur Prophylaxe und Therapie von Pseudomonas aeruginosa-Infektionen | |
| DE19600939C1 (de) | Verfahren zur Trennung von IgG und IgA | |
| DE2515666C3 (de) | Piasminreiche Gammaglobulinfraktion, Verfahren zu deren Herstellung und das Verfahrensprodukt enthaltendes Gammaglobulinpräparat | |
| DE2440927A1 (de) | Verfahren zur herstellung von aktivierten hb-ag-vaccinen | |
| DE2409650C3 (de) | Verwendung wäßriger Lösung von menschlichem Serum-Haptoglobin bei der Bekämpfung von hämolytischen Nierenstörungen | |
| DE2440926C3 (de) | Injizierbarer inaktivierter Impfstoff gegen Hepatitis B und Verfahren zu seiner Herstellung | |
| AT383737B (de) | Verfahren zur verwendung einer immunoglobulin-g enthaltenden fraktion | |
| DE3340487A1 (de) | Neue therapeutische verwendung | |
| CH646609A5 (en) | Gamma-globulin for intravenous injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OAP | Request for examination filed | ||
| OD | Request for examination | ||
| 8281 | Inventor (new situation) |
Free format text: NISHIDA, MASAYUKI, OSAKA, JP YABUSHITA, SADAO, DAITO, JP FUJITA, SHIGERU, MINOO, JP SAKI, TOSHIYUKI, KYOTO, JP |
|
| C3 | Grant after two publication steps (3rd publication) | ||
| 8328 | Change in the person/name/address of the agent |
Free format text: VOSSIUS, V., DIPL.-CHEM. DR.RER.NAT. TAUCHNER, P., DIPL.-CHEM. DR.RER.NAT. HEUNEMANN, D., DIPL.-PHYS. DR.RER.NAT., PAT.-ANWAELTE, 8000 MUENCHEN |
|
| 8328 | Change in the person/name/address of the agent |
Free format text: TAUCHNER, P., DIPL.-CHEM. DR.RER.NAT. HEUNEMANN, D., DIPL.-PHYS. DR.RER.NAT., PAT.-ANWAELTE, 8000 MUENCHEN |
|
| 8339 | Ceased/non-payment of the annual fee |